In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, Vyome said.
Updated Sep 17, 2025 | 8:49 AM GMT-04
Vyome Holdings, Inc. (HIND) announced on Wednesday that its VT-1908 eyedrop has been shown to significantly reduce uveitis scores in preclinical models. Shares of the company rallied by over 60% in pre-market trading on Wednesday.
Uveitis is the inflammation of a part of the eye and is implicated in approximately 30,000 new cases of legal blindness annually in the United States alone, according to Vyome.
In a preclinical model of anterior uveitis, the twice-daily application of VT-1908 eyedrops significantly reduced the uveitis score, and the efficacy of the drug was found to be similar to a clinically used steroid, the company stated.
Get the daily crypto email you’ll actually love to read. It’s value-packed, data-driven, and seasoned with wit.
Get updates to this developing story directly on Stocktwits.
